Introduction-In this study, a structurally modified phosphoramidate scaffold, with improved prostate-specific membrane antigen (PSMA) avidity, stability and in vivo characteristics, as a PET imaging agent for prostate cancer (PCa), was prepared and evaluated.
Introduction
Owing to its unique and ubiquitous expression in prostate cancers (PCa) with limited (100-1000 fold lower) expression in other organs, prostate-specific membrane antigen (PSMA) is an ideal biomarker [1] and has attracted significant attention as a target for imaging [2] [3] [4] [5] [6] [7] and treatment of PCa [8] [9] [10] .
The only FDA-approved single-photon emission computed tomography (SPECT) diagnostic imaging agent for PCa, Prostascint®, an 111 In-labeled antibody that recognizes an intracellular epitope of the PSMA transmembrane protein [11] , is only accessible in damaged or necrotic prostate tumor cells. Even though other antibodies targeted to extracellular epitopes of PSMA have been employed successfully to deliver diagnostic and therapeutic radionuclides [3, [12] [13] [14] , the long accumulation and circulation times, poor tumor penetration, and multiple day imaging procedure result in their suboptimal diagnostic accuracy and reduced clinical use.
In contrast, small-molecule probes possess advantages of drug-like pharmacokinetics, high atom-economy, and reduced production costs. To point, Pomper et al. have pioneered the development of small molecule PSMA-targeted PET and SPECT probes to successfully image prostate tumor xenografts in mouse models, using a urea-based peptidomimetic scaffold with avidity for PSMA's active site [15] [16] [17] [18] . While the pharmacokinetic and imaging profile with these agents appears more superior to antibody-based approaches, washout of the tracer over several hours was observed [15] .
Recently, we demonstrated that our phosphoramidate-based peptidomimetic PSMA inhibitors may be outfitted with imaging payloads without having an adverse effect on their inhibitory capabilities [6, 19] . Our lead irreversible phosphoramidate inhibitor 1, with a serine as the P1 residue and glutamate as the P1′ residue (IC 50 = 14 nM) ( Fig. 1 ) was modified to selectively deliver the tracer to PSMA(+) cells both in vitro and in vivo. When conjugated with a fluorescent dye, 1 was found to accumulate in PSMA(+) cells presumably through the internalization of the PSMA enzyme-inhibitor complex [19] . This phosphoramidate inhibitor 1 has also been validated for SPECT and PET imaging of with PSMA(+) cells and tumors when labeled with 99m Tc and 18 F respectively [6, 7, 20] .
In an effort to further our understanding of the phosphoramidate scaffold's binding to PSMA and to improve the overall in vivo characteristics for human use, we have structurally modified the scaffold with 2-(3-hydroxypropyl)glycine and aminohexanoate, forming a new phosphoramidate inhibitor 3 to improve its binding, stability and imaging efficacy. 
Materials andmethods

Cell lines, reagents and general procedures
LNCaP, CWR22Rv1 and PC-3 cells were obtained from the American Type Culture Collection (Manassas, VA). NCr-nu/nu mice (strain code 088) were purchased from Charles River (Hollister, CA). Z-6-Aminohexanoic acid (CBZ-AH-OH) was purchased from SigmaAldrich (St. Louis, MO). All chemicals and cell-culture reagents were purchased from Fisher Scientific (Sommerville, NJ) or Sigma-Aldrich. All solvents used in chemical reactions were anhydrous and obtained as such from commercial sources or distilled prior to use. All other reagentswere used as supplied unless otherwise stated. Liquid flash chomatography (silica or C18) was carried out using a Flash Plus chromatography system (Biotage, Charlotte, NC). High-resolution mass spectrometry was performed using an ABS 4800 MALDI TOF/TOF Analyzer (Applied Biosystems, Framingham, MA). ESI was performed using API 4000 Electrospray Ionization Triple Quadrupole MS/MS. 1 H NMR chemical shifts were referenced to tetramethylsilane (δ = 0.00 ppm), CDCl 3 (δ = 7.26 ppm) or D 2 O (δ = 4.87 ppm). 13 C NMR chemical shifts were referenced to CDCl 3 (δ = 77.23 ppm). 31 P NMR chemical shifts in CDCl 3 or D 2 O were externally referenced to 85% H 3 PO 4 (δ = 0.00 ppm) in CDCl 3 or D 2 O. Aqueous buffered solutions for in vitro experiments and HPLC chromatography were prepared with deionized distilled water (Milli-Q water system, Millipore, Billerica, MA).
The HPLC analysis and purification system for radioactive compounds were performed on aWaters model 600 Multisolvent System pump equipped with a Shimudzu model SPD-10A UV detector and an in-line radioactivity detector (model 105 s, Carroll and Ramsey Associates, Berkeley, CA) that was coupled to a data collection system (PeakSimple model 304, SRI, Torrance, CA).
Synthesis of phosphoramidate 3 and its fluorinated analogs
The general synthetic sequence of these compounds is shown in Fig. 2 [21] . The reaction mixture was stirred for 6 h in the dark at room temperature. Unreacted 3 was scavenged by adding 25 mg Si-Isocyanate resin (SiliCycle, Inc., Quebec, Canada) with stirring overnight at room temperature. The solution was subsequently centrifuged (7800 rcf, 10min), and the supernatant was lyophilized in a 2 mL microcentrifuge tube. The unreacted and/or hydrolyzed SFB was removed by successively triturating the lyophilized solid with 1 mL portions of DMSO and centrifuging the mixture 
[ 18 F]5-N-Succinimidyl-4-[ 18 F]fluorobenzoate ([ 18 F]SFB)
, prepared in the UCSF cyclotron facility (see Supplementary Information) was coupled to 3 as previously described with minor modifications [6] . 3 (2-3 mg) dissolved in 100 μL of H 2 O, 20 μL of 0.1 M K 2 CO 3 and 50-100 μL of [ 18 F]SFB were added to a one dram vial charged with a stir bar (pH 9.5-10). The coupling reaction took place for 10 minutes at 37 °C. Prior to the in vitro and in vivo studies, the radioconjugate was purified on semi-preparative RP-HPLC using a Phenomenex C18(2) 100 Å, 250 × 10 mm, 5 u column. Linear gradient (20% to 90% over 22 minutes) of solvent B in solvent A (A: 0.1% formic acid in water; B: 0.1% formic acid in acetonitrile) at a flow rate of 5 mL/min with radio-detection and UV detection at 254 nm. [ 18 F]5 peak was collected and concentrated via C18 Plus SPE method using acetonitrile for elution. The concentrated [ 18 F]5 was brought to dryness under reduced pressure and nitrogen streamand reconstituted in saline (0.9% NaCl) for in vitro/in vivo studies. Radiochemical yields ranged between 30 and 50% decay-corrected from [ 18 F]SFB.
PSMA inhibition assay and reversibility assay
The PSMA inhibition assay and the reversibility assay were performed as previously described with minor modifications [19, 22, 23] . Detailed description is provided in the Supplementary Information (Section 2).
Whole cell lysate extraction and western blot analysis
The extraction of PSMA and its analysis by western blot for LNCaP and CWR22Rv1 cells was performed as described previously [24] .
Glutamate carboxypeptidase II expression, purification, crystallization and data collection
Details about PSMA purification, crystallization with 4 and 5 and data collection can be found in the Supplementary Information (Section 3a).
2.5.1.
Structure determination and refinement-Structures were determined by the difference Fourier methods using the structure of the PSMA/NAAG complex (PDB entry 3BXM [25] ) as the template model. Model building was accomplished using Coot [26] , and calculation steps were performed using Refmac 5.1 [27] . The restrains library and the coordinate files for individual inhibitors were prepared using the PRODRG server [28] , and the inhibitors/substrates were fitted into the positive electron density map in the final stages of the refinement.
The stereochemical quality of final models was evaluated using MolProbity [29] , and the final models, together with experimental amplitudes were deposited in the RCSB Protein Data Bank under entry codes 4JZ0 (PSMA/4; deposited as hGCPII/CTT1055) and 4JYW (PSMA/5; deposited as hGCPII/CTT1057). Data collection and structure refinement statistics are provided in the Supplementary Information (Section 3b, Table S1 ).
In vitro cell uptake and internalization studies
LNCaP, CWR22Rv1 and PC-3 cells were cultured in T-75 flasks with complete growth medium (RPMI 1640 containing 10% heat-inactivated fetal calf serum (FBS), 100 units of penicillin and 100 μg/mL streptomycin) in a humidified incubator at 37 °C and 5% CO 2 .
The in vitro cell uptake studies followed the procedure described in our previous work [22] . Detailed description is provided in Supplementary Information (Section 2).
Internalization studies followed the method described for the in vitro cell uptake studies with a minor modification. Detailed description is provided in Supplementary Information (Section 2).
In vivo PET imaging and biodistribution studies
Six to eight-week-old athymic NCr-nu/nu male mice were purchased from Charles River (Hollister, CA). All animal experiments were conducted in accordance with the UCSF IACUC-approved protocol. [ 18 F]5 was evaluated in vivo using mouse xenografts. vein. The anesthetized mice were imaged with 10 min acquisition using a microPET/CT imaging system (Inveon, Siemens, Knoxville, TN) at 1 h and 4 h post injection. PET imaging data were acquired in list mode and reconstructed with the iterative OSEM 2-D reconstruction algorithm provided by the manufacturer.
Biodistribution studies-Four
to five weeks after CWR22Rv1 cells implantation, tumor-bearing mice were anesthetized by isoflurane inhalation and administered with 35-40 μCi of [ 18 F]5 in 150 μL of saline through tail vein injection. For the blocking study at the 4 h time point, animals (n=4) were injected with 250 μg of 1 in 150 μL saline 1 h prior to the injection of [ 18 F]5. At 1 h and 4 h post injection (n = 4 for each time point), these mice were euthanized for biodistribution analysis. Blood was collected by cardiac puncture. Major organs (heart, lung, liver, spleen, kidney, muscle, bone and tumor xenografts) were harvested, weighed, and counted in an automated gamma counter (Wizard 2, PerkinElmer, Waltham, MA). The percent injected dose per gram (%ID/g) of tissue was calculated by comparison with standards of known radioactivity. Statistical analysis was performed using two-tailed student t-test (Microsoft Excel Prism software). A p value of <0.05 was considered statistically significant.
Results
Synthesis of cold standards and radiolabeling precursors
3-hydroxypropylglygine was installed as the P1 residue which was then coupled to the P2 residue Cbz-Glu-OHvia deprotection of its terminal amine to yield benzyl protected 2 or coupled with Boc-Glu-OH to yield precursor I [30] . I was then N-deprotected, and Cbz-AH-OH (aminohexanoic acid linker) was installed followed by global deprotection to give 3 in 87% yield. The fluorobenzamide (FB) derivative, 5 and [ 18 F]5 were synthesized in quantitative yields via coupling of 3 with respective succinamidyl-4-fluorobenzoates (SFB and [ 18 F] SFB) at pH 10 ( Fig. 2) .
No decomposition was observed for 2 at pH 3 over 5 h at 25 °C, whereas 1 exhibited rapid decomposition at pH 6 ( 31 P NMR spectra for evaluation of pH stability can be found in the Supplementary Information, Section 5). 5 was used as a cold standard for optimizing the reversed phase HPLC conditions to aid in the purification of [ 18 F]5.
IC 50 determination and mode of inhibition
The effect of fluorobenzoyl conjugation to the phosphoramidate scaffold on PSMA inhibition was investigated using an HPLC-based assay [23, 31, 32] . As observed with the earlier-generation analog 1, no loss of inhibitory potency was observed when 3 (19 nM)was converted to 5 (0.4 nM) [6, 22] . Additionally, the phosphoramidates 2, 3 and 5 showed irreversible binding to PSMA.
Crystallization of phosphoramidates 4 and 5 with PSMA
X-ray structures of the PSMA/4 and PSMA/5 complexes at resolution of 1.83 Å and 1.73 Å, respectively, were determined using difference Fourier methods.
Placement of both inhibitors within the PSMA-binding pocket can be unambiguously assigned from the electron density map with 5 modeled in two distinct conformations (Fig.  3A) . The positioning of the P1' glutamate and phosphoramidate moieties is virtually identical for both the inhibitors 4 and 5, and both functionalities are engaged in the "canonical" set of interactions with PSMA residues (Fig. 3B) [33, 34] . However, there are substantial differences in the arrangement of P1 and distal parts (beyond the P1 residue) of inhibitors. The P1 carboxylate of the phosphoramidate 4 is directly bonded to Arg534 (2.7 Å), Arg536 (2.9 Å), and Asn519 (3.0 Å), the P2 carboxylate accepts a hydrogen bond from the hydroxyl group of Tyr234, while the distal fluorobenzoyl moiety is packed against the side chain of Tyr700. In comparison, the P1 carboxylate of the phosphoramidate 5, forms a salt bridge with the guanidinium group of Arg536 (3.1 and 3.1 Å) and is also engaged in several water-mediated contacts with the side chains of Arg536, Glu457, Arg534, Asn519, and Asp453. Other non-carbon atoms of the 20 Å linker donate or accept a multitude of hydrogen bonds to/from water molecules filling the entrance funnel. Additionally, the mainchain carbonyl accepts hydrogen bond from the guanidinium group of Arg463 (2.8 Å), while the P2 carboxylate is hydrogen bonded to the amide group of the Asn698 side chain (2.9 Å; Supplementary Information, Section 3c). The distal (P2) part of the linker connecting the terminal fluoro-benzoyl moiety, is present in two distinct conformations.
Most importantly, the terminal fluoro-benzoyl functionality (also in two overlapping conformations) is inserted into the arene-binding cleft located at the "entrance lid" of the enzyme (Fig. 3B) [35, 36] .
The plane of the fluoro-benzoyl ring is virtually parallel to both indole and guanidinium groups of Trp541 and Arg511, respectively, of the arene-binding cleft, and these two functionalities likely contribute considerably to the overall inhibitor binding.
In vitro uptake and internalization study
The western blot analysis confirmed nearly 5-fold greater PSMA expression in the LNCaP cells as compared to the CWR22Rv1 cells ( Supplementary Information, Section 4) . This difference in PSMA expression levels between the two cell lines was also mirrored in the cell uptake of [ 18 F]5. There was a 9.8-fold and 6.6-fold higher cell uptake for LNCaP cells as compared to the CWR22Rv1 cells, at 1 h and 4 h respectively (Table 1) . Increased cell uptake in both the cell lines was observed over 4 h incubation with [ 18 F]5 ( Table 1) . The percent uptake in LNCaP cells showed about 1.5-fold enhancement while CWR22Rv1 cells showed a 2-fold increased uptake from 1 hr to 4 h. Insignificant uptake for PC-3 cells was observed at both 1 and 4 h. Table 1) . The CWR22Rv1 cells, which have been used as tumor xenografts for in vivo imaging and biodistribution, showed 81% and 91% internalization at 1 h and 4 h respectively.
The internalization of [ 18 F]5 in LNCaP cells was 93% at 1 h and 92% at 4 h (
In vivo imaging and biodistribution study
As shown in Fig. 4 , the uptake of The ex vivo biodistribution data confirmed the imaging findings (Table 2 and Fig. 5 ). There was rapid uptake of the tracer in the PSMA positive tumor within the first hour with significant clearance from the blood and other non-PSMA tissues over the 4 h study. At 1 h post-injection, the PSMA(+) tumor accumulation was 2.35 ± 0.91 %ID/g with a tumor-toblood ratio of 22:1. At 4 h post-injection, the tumor accumulation remained at 2.33 ± 0.50 %ID/g while more than 10-fold clearance from the blood provided a tumor-to-blood ratio of 265:1. The kidneys showed expected high uptake and retention of the tracer with 18.12 ± 2.21 %ID/g and 17.17± 4.13 %ID/g at 1 h and 4 h, respectively. Competition study with cold phosphoramidate 1 injected an hour prior to the administration of [ 18 F]5 showed significant decreased in kidney and tumor uptake by 67% (p=0.0010) and 91% (p= 0.0003), respectively.
Discussion
The first generation 18 F-labeled phosphoramidate inhibitor, 1, has previously demonstrated desirable PSMA targeting properties in vitro in LNCaP cells and in vivo in LNCaP xenografts. In this work, we have improved the acid-stability of the scaffold by incorporation of a P1 2-(3-hydroxypropyl)glycine residue. We hypothesize that the installation of 2 extra methylene units in the P1 residue of 2 as compared to 1 prevents the collapse of the phosphoramidate by release of P1′ glutamate due to protonation of the amine at physiological pH. This provided greater acid stability to 2 compared to 1 and aided purification of the radiolabeled analog via the use of acid modifiers in the HPLC mobile phase. Further molecular elaboration off the P2 amino group with the aminohexanoic linker and fluorobenzoylation of the terminal amine using SFB gave 5, which displayed high affinity for PSMA. As observed in the case of 4, functionalization via the N-terminal amine of the core phosphoramidate causes no loss of inhibition, and these modified inhibitors still maintain an irreversible mode of binding for PSMA.
The synthetic procedure is highly translatable to routine procedures and scale-ups. Preparation of SFB can be easily achieved using several automated synthesis units and commercially available cassettes. The single step addition of SFB to 3, to generate the desired agent, may be performed at room temperature, and has high coupling yields. In a pre-IND discussion with the FDA regarding the first-in-man studies with [ 18 F]5, the FDA did not raise any concerns about the non-traditional prosthetic labeling approach for this radiotracer.
To gather insight into the modes of interaction of 5 with PSMA and compare it with our previous agent 4, both compounds were co-crystallized with the extracellular domain of PSMA. Co-crystallization of 5 with PSMA revealed several additional interactions that may contribute toward its enhanced affinity towards PSMA, as compared to analog 4. Apart from many pronounced interactions of the P1/P2 residues of 5 with the enzyme, a multitude of H-bonds is formed with the non-carbon atoms of the 20 Å AH linker within the entrance funnel. It is interesting to note that the conformation of the Arg536 side chain in the PSMA/5 complex differs from "typical" conformations of this "invariable" arginine observed in complexes reported previously [34, 35] , most likely due to "the pulling effect" of the P1 carboxylate. The most prominent interaction however, was the π-stacking, π-cationic interaction of the fluorobenzamido ring with the Arg511/Trp541 and Arg 463 residues respectively, known as the arene-binding cleft located at the entrance lid of the protein, behaving in a bidentate fashion and contributing considerably to the overall affinity and irreversibility of 5. This observation mirrors similar finding for GCPII/ARM-P complexes [36] . Although differing in both the linker length and the chemistry of their distal groups, binding modes of 5 and ARM-P are very similar, strengthening the notion of the arenebinding cleft as a "universal" structural motif exploitable for the design of bidentate GCPII inhibitors.
In vitro cell uptake experiments showed elevated uptake of [ 18 F]5 in the PSMA(+), LNCaP and CWR22Rv1 cells compared to the PSMA(−) PC3 cells. The low uptake in PC-3 cells was expected due to absence of PSMA expression in the cell line [37] . There was also a significantly greater uptake in the LNCaP cells compared to the CWR22Rv1 cells, consistent with the known 3-to 5-fold higher concentration of PSMA in LNCaP cells, which was further confirmed by western blot experiments. The [ 18 F]5 rapidly internalized in both PSMA(+) cell types with more than 80% of the compound associated with CWR22Rv1 cells and more than 90% with LNCaP cells at 1 h. These internalization values were much higher than what has been typically known for the reported urea-based agents [38] , presumably due to the irreversible binding of the phosphoramidates [19, 22] . Based on these observations, it was expected that in vivo tumor uptake of the radiotracer would occur shortly after administration, retain within the tumor over several hours, and develop greater contrast with the background tissues.
Even though the LNCaP cell line, used in the study of our first generation analog [ 18 F]4, exhibits greater PSMA expression, its growth rate and proliferation as tumor xenografts in animal models is unpredictable and often leads to tumor necrosis. In contrast, CWR22Rv1 cell lines have moderate PSMA expression but are predictable in their growth as tumor xenografts. In addition, the cellular PSMA concentration in the CRW22Rv1 cells is more akin to the expression levels expected in human prostate cancer metastases. Therefore, for the in vivo studies, the mice were implanted with CWR22Rv1 xenografts. Imaging and biodistribution was performed at 1 and 4 h post-injection of [ 18 F]5, in contrast to the 2 h postinjection study performed in the case of our previous agent [ 18 F]4. While there cannot be a head-to-head comparison, since the studies of the two compounds occur at different time points and tumor types (LNCaP vs. CWR22Rv1), they inform the reader of an overall trend in the uptake and clearance of the radiotracers.
The overall pharmacokinetics of [ 18 F]4 and [ 18 F]5 are comparable with very low non-target uptake, with the exception of the kidneys. The elevated kidney uptake was expected due to the known high PSMA expression in the mouse kidneys, an artifact of this animal model [39] ; and thus can be treated as a good secondary indicator of PSMA specificity. The kidney uptake was for [ 18 
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